达雷妥尤单抗联合硼替佐米、环磷酰胺和地塞米松治疗初诊和复发多发性骨髓瘤:LYRA研究
LYRA研究在美国社区人群中评估D-VCd方案治疗初诊多发性骨髓瘤(NDMM)和复发多发性骨髓瘤(RMM)。NDMM患者4周期诱导后≥VGPR率为44%(主要终点),总缓解率79%,诱导结束时分别为56%和81%,12个月无进展生存率87%。RMM患者也观察到疗效,D-VCd总体耐受良好。
要点
- NDMM患者4周期诱导后≥VGPR率为44%,总缓解率79%。
- NDMM患者诱导结束时≥VGPR率56%,总缓解率81%,12个月PFS率87%。
- 疲乏(59%)和中性粒细胞减少(13%)分别是最常见TEAE和3/4级TEAE。
核心结论
- D-VCd方案总体耐受良好,达雷妥尤单抗首剂分次给药可行。
- NDMM患者4周期后≥VGPR率为44%,1年PFS率为87%。
- RMM患者也观察到疗效。
研究设计与样本
- 美国社区研究,评估D-VCd方案在NDMM和RMM中的疗效与安全性。
- 86例NDMM和14例RMM患者接受至少1次治疗剂量。
- 患者接受4-8周期诱导:硼替佐米1.5 mg/m2、环磷酰胺300 mg/m2、地塞米松40 mg每周;达雷妥尤单抗静脉16 mg/kg按获批方案给药,第1周期首剂分次给药。
- 符合条件的患者接受自体造血干细胞移植。所有患者接受≤12次达雷妥尤单抗维持治疗,每月一次。
主要发现
- NDMM患者4周期诱导后≥VGPR率为44%(主要终点),总缓解率79%;诱导结束时≥VGPR率56%,总缓解率81%。
- NDMM患者12个月无进展生存率为87%。
- RMM患者也观察到疗效。
- 疲乏(59%)是最常见治疗中出现的不良事件(TEAE),中性粒细胞减少(13%)是最常见3/4级TEAE。
- 输注反应发生率54%,主要发生在首次剂量,多为轻度(3级占2%);前2次达雷妥尤单抗输注中位时间分别为4.5小时和3.8小时。
关键数值与推荐
- NDMM患者4周期诱导后≥VGPR率为44%,总缓解率79%。
- NDMM患者诱导结束时≥VGPR率56%,总缓解率81%。
- NDMM患者12个月无进展生存率为87%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This United States community study evaluated the combination of daratumumab, bortezomib, cyclophosphamide and dexamethasone (D-VCd) in newly diagnosed multiple myeloma (NDMM) and relapsed multiple myeloma (RMM). Patients received 4-8 induction cycles of bortezomib 1·5 mg/m2 , cyclophosphamide 300 mg/m2 and dexamethasone 40 mg weekly. Intravenous daratumumab 16 mg/kg was administered as approved except for a split-first dose in Cycle 1. Eligible patients underwent autologous stem cell transplantation. All patients received ≤12 daratumumab maintenance doses monthly. Eighty-six NDMM and 14 RMM patients received ≥1 treatment dose. In NDMM patients, very good partial response or better (≥VGPR) and overall response rates after 4 induction cycles were 44% (primary endpoint) and 79%, respectively, and 56% and 81% at end of induction. The 12-month progression-free survival (PFS) rate was 87%. Efficacy was also observed in RMM patients. Fatigue (59%) and neutropenia (13%) were the most frequent treatment-emergent adverse event (TEAE) and grade 3/4 TEAE, respectively. Infusion reactions occurred in 54% of patients, primarily during the first dose, and were mild (2% grade 3). The first 2 daratumumab infusions were 4·5 and 3·8 h (median). Overall, D-VCd was well tolerated, split-first daratumumab dosing was feasible, the ≥VGPR rate after 4 cycles was 44% and the 1-year PFS rate was 87%.
引用
- Yimer H, Melear J, Faber E, et al. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Br J Haematol. 2019. PMID: 30828799. doi:10.1111/bjh.15806
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。